BACKGROUND:
Ten-year follow-up data from the US Food and Drug Administration investigational device exemption trial comparing BRYAN R Cervical Disc (Medtronic, Dublin, Ireland) arthroplasty to anterior cervical discectomy and fusion (ACDF) demonstrated that disc arthroplasty maintained range of motion and improvements in overall success and neck disability. OBJECTIVE: To compare the 10-yr rates of symptomatic adjacent level disease requiring surgery (SALDRS). METHODS: Prospective randomized trial data were analyzed comparing BRYAN R Cervical Disc arthroplasty to ACDF for single-level cervical disc disease with concordant radiculopathy or myelopathy with clinicoradiographic analysis at 10 yr. Secondarily, 84-mo data were pooled with PRESTIGE R Cervical Disc arthroplasty (Medtronic) study data to provide overall rates of SALDRS. RESULTS: Significantly greater overall success was maintained at every postoperative interval with an overall success rate of 81.3% with BRYAN R disc and 66.3% with ACDF (P = .005) without loss of motion preservation (8.69 • vs 0.60 • ). Reoperation at adjacent levels up to the 120-mo visit was 9.7% in the arthroplasty group and 15.8% in the ACDF group (P = .146). The combined data from BRYAN R and Prestige ST demonstrate that BRYAN R and Prestige disc groups had a lower rate of second surgeries at the adjacent levels, up to the 84-mo visit, compared to the combined ACDF groups (6.9% vs 11.7%; P = .023). CONCLUSION: Compared with ACDF, fewer patients with the BRYAN R disc required surgery for symptomatic adjacent level degeneration, but this did not achieve statistical significance. Analysis of combined study data using Bryan and Prestige discs shows significant differences in SADLRS as early as 7 yr. www.neurosurgery-online.com A nterior cervical discectomy and fusion (ACDF) has long been regarded as a relatively safe, versatile, and effective treatment for cervical spondylotic disease and other cervical pathologies with high rates of success and an acceptable periprocedural complication rate. [1] [2] [3] However, one overarching concern ABBREVIATIONS: ACDF, anterior cervical discectomy and fusion; CDA, cervical disc arthroplasty; SALD, symptomatic adjacent level degeneration; NDI, neck disability index; RCT, randomized controlled trial; ROM, range of motion; SALDRS, symptomatic adjacent level disease requiring surgery
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has been the development of symptomatic adjacent level degeneration (SALD) after ACDF, thought to be the product of increased segmental motion, intradiscal pressures, articular surface loading, and strain. [4] [5] [6] [7] [8] This undesired outcome was first described retrospectively in 374 patients by Hilibrand et al, 9 who cited a 25.6% 10-yr rate of SALD, or 2.9% per year. Perhaps most valuable to surgeons is a determination of symptomatic adjacent level disease requiring surgery (SALDRS) at that adjacent level. In Hilibrand et al, 9 72% of patients that developed SALD failed nonsurgical management and were offered surgery, for a rate of 2.2% per year or a 10-yr absolute risk of 19.2%. In the largest retrospective analysis of SALDRS including 1038 patients, Lee et al 10 found a rate of SALDRS to be 2.4% per year.
The BRYAN Cervical Disc prosthesis (Medtronic, Dublin, Ireland) was introduced clinically in the USA in 2002, 11, 12 followed shortly by favorable trial results from other cervical disc arthroplasty (CDA) devices. [13] [14] [15] [16] Proponents of CDA have argued that equivalent clinical improvements to ACDF could be achieved while simultaneously preserving cervical range of motion (ROM). In 1 meta-analysis of 17 studies and 3122 patients, ACDF was found to have a slightly lower overall success rate as compared to CDA (Relative Risk = 0.84), but very few other differences were detected. 17 In a meta-analysis of 8 prospective, randomized controlled trials (RCTs) by Zhu et al 18 and 20 RCTs by Xie et al, 19 significantly greater clinical outcomes with CDA were observed at the expense of prolonged intraoperative durations. However, interpretation of meta-analyses in CDA are limited by differences in study design, indication, device use, outcomes measures used, and a short follow-up duration of 4 to 6 yr. 20 Increased attention has centered on determining the difference in SALD between ACDF and CDA, 14, [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] with the hypothesis that CDA may restore favorable kinematics of the cervical spine, and therefore, will lower rates of SALD. 18, [29] [30] [31] The primary purpose of this study is to investigate rates of SALDRS in a 10-yr follow-up of patients enrolled in a prospective, multicenter, randomized controlled IDE study comparing BRYAN R Cervical Disc (Medtronic) to ACDF for the treatment of single-level cervical disease (Figure 1 ).
METHODS

Subjects and Study Design
Institutional review board approval and patient consent were obtained at all study sites for initial enrollment and extension of the observational period to 10 yr. The initial patient population utilized herein are study participants from a prospective, randomized, multicenter study comparing ACDF to BRYAN R Cervical Disc (Medtronic) for single-level cervical degenerative disc disease, as previously reported at [24] [25] [26] [27] [28] [29] [30] [31] [32] and 48-mo 33 follow-up periods. The clinical trial can be accessed on the national registry with the identification number (NCT00437190). All enrolled patients were greater than 21 yr of age with single-level cervical disc disease with concordant radicular or myelopathic symptoms attributable to disc herniation or focal osteophytes. All patients underwent greater than 6 wk of nonoperative management. Subjects were enrolled in a 1:1 ratio to either BRYAN R CDA or ACDF using a standardized anterior cervical plate (Atlantis; Medtronic) and allograft bone substrate (Cornerstone; Medtronic) at 30 investigational sites. All subjects randomized to CDA received a 2-wk postoperative course of a nonsteroidal anti-inflammatory medication, and all routine postoperative activity restrictions and bracing were managed at the surgeon's discretion. In addition to the preoperative evaluation, defined study intervals included the time of surgery, discharge, 6 wk, 3, 6, 12, 24, 48, 72, 96, and 120 mo postoperatively.
The Prestige R Cervical Disc arthroplasty (Medtronic) IDE study has 84-mo clinical follow-up data for 395 patients in an IDE study that utilized the same inclusion criteria for enrolment and end-point analysis for both arthroplasty or fusion as the Bryan R IDE (Medtronic) study. The Prestige R IDE study also demonstrated maintenance of motion while sustaining improvements in clinical outcomes. 13 The authors pooled data from these 2 aforementioned trials at the 84-mo mark and compared the rates of SALDRS in the arthroplasty vs ACDF groups for the pooled data.
Outcomes Assessment
Routine collection by study investigator or trained staff consisted of neck disability index (NDI), 34, 35 Short Form-36, 36 numeric rating scales for neck and arm pain, and standardized neurological examinations. Neurological success was defined as maintenance or improvement of motor, sensory function, and reflexes. Serial radiographic assessment by independent radiologist was conducted preoperative, postoperatively prior to discharge, and at 3, 6, 12, 24, 48, 72, 96, and 120 mo. Prospective adverse event collection and categorization, assessment of causality, and severity grading were in accordance with World Health Organization standards and criteria. 37 Using the Cobb method on lateral cervical radiographs, the cervical ROM at the cervical level of interest was measured from the mean of 2 measurements. 38 
Statistical Methods
A description of the primary analysis dataset for patients receiving one of the 2 surgical treatments has been described. 12, 33 Treatment failure was defined as the inability to achieve improvement of at least 15 points in the NDI, maintenance or improvement of baseline neurological exam, adverse event occurrence, or the occurrence of a secondary surgery. For subjects who have secondary surgeries classified as failure, the outcomes before the secondary surgery will be carried forward to the later time period. Patient demographic and preoperative variables were analyzed with analysis of variance and Fisher exact test for continuous and categorical variables, respectively. Comparisons of postoperative variables were conducted with analysis of covariance, utilizing the initial preoperative variable as the covariate. A paired t-test was used to determine significance of improvement within each treatment group from the baseline. The comparison of success rate of a binary variable between 2 groups was assessed using the z-test of the normal approximation to the binomial distributions with standard error derived using Farrington and Manning Method. The comparison of adverse events, secondary surgery, and return-to-work was carried out using log rank test for time to event data. While the comparison of success rates between the 2 groups and the comparison of improvement of scores from baseline between the 2 groups used 1-sided P-value, 2-sided P-values were used for surgery and return-to-work data, adverse events and additional surgical procedures.
Preoperative Comparison
In the BRYAN TM study (Medtronic), 463 subjects were enrolled and randomized between May 2002 and October 2004, with 242 and 221 assigned to the arthroplasty and fusion group, respectively. At 4 yr, 181 (75%) arthroplasty and 138 (62%) fusion patients were available for follow-up. 33 At 10-yr follow-up, 130 (54%) arthroplasty and 105 (47%) fusion subjects were available, with 128 and 104, respectively, evaluated for overall success.
RESULTS
In the arthroplasty group, a significantly greater overall success was maintained at every postoperative interval, and at 120 mo, the overall success rate was 81.3% with BRYAN R disc (Medtronic) and 66.3% with ACDF (P = .005, Figure 2) . Similarly, at final follow-up, NDI success was significantly greater in the arthroplasty group (90.5% vs 75.7%, P = .001). There was no significant difference in neurological success (92.1% vs 95.1%, P = .826). The incidence of SALDRS at the adjacent level was 15.8% in the ACDF group and 9.7% in the arthroplasty group, although this difference did not reach statistical significance (P = .146, Figure 3) . Overall, at 10 yr, NDI score improvements were significantly greater in the arthroplasty group (38.3 vs 31.1, P = .010). At 10 yr, cervical ROM was preserved in the arthroplasty group as compared to the ACDF group (8.69
• vs 0.60 • , Figure 4 ). Survival analysis of pooled data from the definitive IDE studies of the BRYAN R and Prestige R Cervical Disc (Medtronic) was performed. The cumulative rate of SALDRS at 84 mo was 6.9% and 11.7% in the cervical arthroplasty and fusion groups, respectively. The P-value for the comparison of the treatment effect based on the Cox Proportional Hazards Model adjusted for study effect is P = .023.
DISCUSSION
Understanding the historically reported incidence of SALDRS is important when interpreting the 6.1% decreased rate of SALDRS found in the 10-yr prospective data obtained from the BRYAN R (Medtronic) Cohort, which, while appreciable, did not achieve significance. Returning to the Hilibrand et al study, 9 a 2.9% annual rate of SALD was found, with an annual rate of 2.2% of patients required reoperation. In the 10-yr analysis of BRYAN R Disc data, the rate of SALDRS was 1.58% per year in the ACDF cohort, much lower than historically reported. Moreover, it is important to highlight that the aforementioned historical rates for comparison were retrospectively obtained, which for a number of methodological reasons could contribute to this difference. Future randomized clinical studies that base their enrollment numbers on studies such as that by Hilibrand et al 9 could conceivably be underpowered. Either a larger patient population or further follow-up may be required to detect the true difference in the rate of SALDRS.
Reoperation after ACDF is among the most common complications reported in prior large series, with reoperation rates as high as 15% at 3 yr. 39 Again, in the Hilibrand et al study, 9 the annual rate of SALDRS was 2.2% and the 10-yr rate of reoperation for SALDRS was 19%. In a more recent study of a series nearly 3 times larger, Lee et al 10 calculated a 2% annual rate and 22% 10-yr reoperation rate for SALD. In addition to highlighting reoperation rates, these authors note several risk factors for adjacent level degeneration. Specifically, tobacco use, female gender, and fusion of 1-or 2-level fusion segments were identified by Lee and coinvestigators 10 to be risk factors for development of adjacent level pathology. In contrast, Hilibrand et al 9 found the presence of the adjacent level disc space, when either C5 and C6 or C6 and C7, increased ROM at any adjacent level and increased age, to be significant risk factors for the development of adjacent level disease. Concerns related to loss of segmental motion, pseudoarthrosis, and adjacent level disease led to the increased interest in cervical arthroplasty. The definition of adjacent level disease can vary among studies, and for this reason the authors have favored the use of a more clinically relevant criterion allowing for a more meaningful comparison amongst studies, such as SALD and SALDRS. 10, 20 Park et al 40 best illustrate this point, in evaluating ossification of the adjacent level as a surrogate marker for adjacent level disease, specifically finding a plate-todisc distance of less than 5 mm on lateral radiograph to be a significant risk factor for the development of adjacent level ossification and the requirement for reoperation. A subsequent study by Goffin et al, 41 although evaluating primarily a trauma population consisting of younger patients, did not find any influence of adjacent level ossification with the development of myelopathy, radiculopathy, or cervical instability. However, van Eck et al 39 analyzed 672 consecutive patients who underwent ACDF and did not find age, gender, tobacco use, number of levels fused, BMI, or plate-to-disc distance to be significant in developing adjacent segment disease. Therefore, given the general lack of agreement on the risk factors for adjacent segment pathology, the authors argue that the most clinically relevant instrument for adjacent segment disease is that requiring an operation, at the cost of a longer follow-up duration needed to identify a significant difference. Long-term studies are critical in assessing the impact of CDA on SALD, as well as device wear, safety, and maintenance of clinical benefit. With the publication of data from prospective studies with longer follow-up durations, increased attention is being paid to whether the CDA device will result in a significantly greater clinical improvement and lower rates of SALDRS.
Previously published results of a multicenter, randomized trial comparing BRYAN R Cervical Disc (Medtronic) arthroplasty to ACDF for single-level degenerative disc disease with concordant myelopathy or radiculopathy showed a significant benefit in terms of overall success ( Figure 2) and NDI success at [24] [25] [26] [27] [28] [29] [30] [31] [32] and 48-mo 33 follow-up, and most recently with 10-yr multicenter data. 42 These results were upheld in the subsequent 10-yr follow-up in overall success rate and neck disability success rate. While significantly greater improvements in VAS neck scores were previously encountered in the arthroplasty group at every follow-up interval through 48 mo, 33 degradation of this treatment effect was observed with VAS neck and arm pain at 10 yr. This 10-yr prospective data of randomized, clinical trial data comparing CDA to ACDF upholds the long-term clinical benefit observed with BRYAN R Cervical Disc arthroplasty for singlelevel cervical disc disease. Similar clinical improvements have been observed in another recent 10-yr prospective study with the BRYAN R disc. 31 Moreover, 10-yr noncomparative prospective data were published utilizing BRYAN R Cervical Disc for the treatment of single-level cervical disc disease attributable to radiculopathy and/or myelopathy. 31 Although lacking an ACDF comparative cohort, this study showed preservation in the overall clinical benefit with arthroplasty, providing valuable clinical data beyond the interim 4-and 6-yr reports. 43 Importantly, maintenance of cervical motion and clinical benefit was seen, with a much higher rate of follow-up (81%, 72 of 89), as the authors represented a single participating center from the definitive BRYAN R study.
Reoperation at the Adjacent Level
Evaluating SALD becomes most valuable with long-term follow-up such as with emerging 7 and 10 yr reports. In the present study of the BRYAN R Disc (Medtronic) with 10-yr follow-up, the authors evaluated the rate of adjacent level reoperation between CDA and ACDF, finding 9.7% and 15.8% in the respective rates of SALDRS. While this difference was 6.1% lower rate favoring arthroplasty, it failed to achieve significance (P = .146; Figure 3) . In all likelihood, the overall low and less than predicted incidence of SALDRS in the fusion group and loss to follow-up for both has increased the number of overall cases required to achieve statistical significance in comparing cervical arthroplasty vs fusion.
With the Prestige R Cervical Disc (Medtronic), at 7 yr, Burkus et al 13 reported a significantly lower rate of SALDRS with Prestige R Cervical Disc as compared with ACDF, with 11 (4.6%) and 24 (11.9%) patients having SALDRS (P = .0008). In that, the inclusion criteria and end points remained the same in both the BRYAN R (Medtronic) and Prestige R studies-pooling data to obtain greater numbers of subjects to assess global SALDRS was performed. When the authors pool the data from the two studies, the rates of SALDRS at 84 mo were 6.9% and 11.7% in the cervical arthroplasty and fusion groups, respectively (P = .023; Figure 5 ). These findings and the increased disparity in SALDRS between groups over time suggests that future follow-up will be equally beneficial. Similar long-term findings have been reported with different CDA devices in prospective RCTs. Jannsen et al 44 present their results from a 7-yr analysis comparing another CDA device, ProDisc-C R (DePuy Synthes Spine, Raynham, Massachusetts) to ACDF, reporting an excellent 7-yr follow-up rate of 91.9% (n = 79) and 92.4% (n = 73) in the CDA and ACDF groups, respectively. In the ProDisc-C R study, a significantly lower reoperation rate was observed with ProDisc-C R , with 19 ACDF patients (18%) undergoing 30 secondary operations vs only 7 (7%) with ProDisc-C R (P = .02). When evaluating adjacent level reoperation alone, with ProDisc-C R , 6 patients underwent 6 reoperations compared to 22 reoperations in 13 patients with ACDF, and a hazard ratio for secondary surgery at the adjacent level was 3.624 (P = .0103). 44 Meta-analyses are utilized by authors to show differences between CDA and ACDF. Previously reported meta-analysis comparing CDA and ACDF clinical outcomes have found a difference in reoperation rates favoring CDA. 18, 20, 22, 24, 25, 45, 46 Zhong et al 24 found 12 RCTs comparing ACDF to CDA, and the overall frequency of reoperation at the adjacent level was 3% with CDA vs 8% in the ACDF group over approximately 4 yr. Similarly, lower reoperation rates were found in meta-analysis by Chang 45 and Zhu. 18 There is one caveat to the reliance on these studies, which is illustrated in the meta-analysis by Harrod et al 20 countercurrent to the literature. In this analysis, overall rates of radiographic and SALD were found to be similar between ACDF and CDA. Most importantly, numerous methodological variations between studies prevent the fair interpretation of meta-analysis arthroplasty data as pertaining to SALDRS due to inconsistent blinding of radiographic interpretation, industry funding, device manufacturer, limited follow-up duration, and heterogeneous patient populations. 20 Therefore, long-term study results from prospective randomized clinical trials such as the present 10-yr followup data analyzed represents the highest quality data available for analysis. Even more so, pooling of data from the BRYAN and Prestige studies (both Medtronic) is useful, given the similarities in design between these 2 studies. However, one predominant limitation miring the interpretation of the BRYAN disc study and the long-term results is the attrition rate not similarly encountered in the Prestige study. At 24 mo, of the 230 (95%) and 194 (88%) of the respective arthroplasty and ACDF patients that were available for follow-up, 32 only 130 (54%) patients assigned to arthroplasty and 105 (47%) of the patients assigned to ACDF were remaining at 10 yr. This decreased follow-up was not unexpected, in lieu of the attrition bias present due to a high drop off encountered in the 48-mo study results. 33 Sasso et al 42 recently published prospective outcomes for 47 patients from a single participating center in the aforementioned FDA IDE study, with the value being their single-center high follow-up rate of 86.4% (19 patients) and 92% (23 patients) for ACDF and CDA, respectively. Of 2 reoperations in the CDA cohort, 1 patient (4.5%) required reoperation for adjacent level disease, while 6 (26%) required adjacent level reoperation in the ACDF cohort required. Moreover, the overall reoperation rate was 8% and 32% for CDA and ACDF, suggesting that CDA was providing a potential biomechanical advantage at the adjacent level.
42
CONCLUSION
Compared with ACDF, fewer patients with CDA required surgery for symptomatic adjacent level degeneration, but this did not achieve statistical significance. However, when data from 2 prospective, randomized studies with similar inclusion and exclusion criteria were combined to increase the power of the assessment, a significant difference in SADLRS was observed at 7-yr follow-up. 
